HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial:: an extended virology study

被引:25
作者
Aboulker, JP [1 ]
Babiker, AG [1 ]
Brun-Vézinet, F [1 ]
Darbyshire, JH [1 ]
Flandre, P [1 ]
Gazzard, B [1 ]
Nunn, AJ [1 ]
Goodall, R [1 ]
Aber, V [1 ]
Bragman, K [1 ]
Breckenridge, AM [1 ]
Carbon, C [1 ]
Charreau, I [1 ]
Chene, G [1 ]
Collis, P [1 ]
Cooper, D [1 ]
Dormont, J [1 ]
Fiddian, P [1 ]
Flepp, M [1 ]
Goebel, FD [1 ]
Hooker, M [1 ]
Lange, J [1 ]
Lüthy, R [1 ]
Peto, TEA [1 ]
Reiss, P [1 ]
Seligmann, M [1 ]
Stone, AB [1 ]
Thomis, J [1 ]
Vella, S [1 ]
Walckenaer, G [1 ]
Warrell, D [1 ]
Weller, IVD [1 ]
Wilber, R [1 ]
Yeni, P [1 ]
Yeo, J [1 ]
Withnall, R [1 ]
Goudsmit, J [1 ]
Huraux, JM [1 ]
van der Noorda, J [1 ]
Weiss, R [1 ]
Boucher, C [1 ]
Schuurman, R [1 ]
Descamps, D [1 ]
Jeffries, D [1 ]
Tedder, R [1 ]
Weber, J [1 ]
Krzyanowski, C [1 ]
Weverling, G [1 ]
机构
[1] UCL, Sch Med, Mortimer Market Ctr, MRC,Clin Trials Unit, London WC1E 6AU, England
关键词
antiviral therapy; progression; HIV-1; RNA; viral load;
D O I
10.1097/00002030-199901140-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To assess changes in HIV RNA and their relationship to disease progression. Design and setting: Delta was a randomized double-blind trial comparing zidovudine (ZDV) monotherapy with ZDV plus didanosine (ddl) or ZDV plus zalcitabine (ddC). Participants had AIDS (with CD4 cell counts above 50 x 10(6)/l), AIDS-related complex, or were asymptomatic with CD4 cell counts below 350 x 10(6)/l. The trial included both ZDV-naive and ZDV-experienced participants. Participants: A total of 1280 participants in the Delta trial whose serum samples had been stored at -70 degrees C and who had a minimum of one sample taken before the start of treatment and at least one later sample. Methods: HIV-1 RNA quantification was performed using the nucleic acid sequence-based amplification HIV-1 RNA quantitative assay with a cut-off of 800 copies/ml. Results: Reductions in HIV RNA by treatment group were consistent with the clinical results; in ZDV-naive participants the maximum median fall occurred at 4 weeks for all three groups (ZDV, 0.54 log(10) copies/ml; ZDV-ddl, 1.38 log(10) copies/ml; ZDV-ddC, 1.31 log(10), copies/ml). On average the reductions were smaller in ZDV-experienced participants but the difference between the monotherapy and combination arms was very similar in ZDV-naive and experienced participants. Baseline HIV RNA levels, adjusted for CD4 cell counts were highly predictive of time to virological response (HIV RNA < 800 copies/ml); HIV RNA nadirs achieved were predictive of survival. Viral load rebound following response was independent of treatment group and previous ZDV therapy. Conclusions: Virological changes in response to treatment are of Value in assessing prognosis and the activity of new therapies; in particular, there is a strong association between the minimum HIV RNA achieved in the first 16 weeks and subsequent clinical response. CD4 cell counts are independently predictive of response. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:57 / 65
页数:9
相关论文
共 14 条
  • [1] Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1
  • [2] HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial
    BrunVezinet, F
    Boucher, C
    Loveday, C
    Descamps, D
    Fauveau, V
    Izopet, J
    Jeffries, D
    Kaye, S
    Krzyanowski, C
    Nunn, A
    Schuurman, R
    Seigneurin, JM
    Tamalet, C
    Tedder, R
    Weber, J
    Weverling, GJ
    Aber, V
    Aboulker, JP
    Babiker, AG
    Bragman, K
    Breckenridge, AM
    Carbon, C
    Charreau, I
    Chene, G
    Collis, P
    Cooper, D
    Darbyshire, JH
    Dormont, J
    Fiddian, P
    Flepp, M
    Gazzard, B
    Goebel, FD
    Hooker, M
    Lange, J
    Luthy, R
    Peto, TEA
    Reiss, P
    Seligmann, M
    Stone, AB
    Thomis, J
    Vella, S
    Walckenaer, G
    Warrell, D
    Weller, IVD
    Wilber, R
    Yeni, P
    Yeo, J
    Withnall, R
    Babiker, A
    Bloch, J
    [J]. LANCET, 1997, 350 (9083) : 983 - 990
  • [3] The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter
    Katzenstein, DA
    Hammer, SM
    Hughes, MD
    Gundacker, H
    Jackson, JB
    Fiscus, S
    Rasheed, S
    Elbeik, T
    Reichman, R
    Japour, A
    Merigan, TC
    Hirsch, MS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (15) : 1091 - 1098
  • [4] Plasma viral load and CD4(+) lymphocytes as prognostic markers of HIV-1 infection
    Mellors, JW
    Munoz, A
    Giorgi, JV
    Margolick, JB
    Tassoni, CJ
    Gupta, P
    Kingsley, LA
    Todd, JA
    Saah, AJ
    Detels, R
    Phair, JP
    Rinaldo, CR
    [J]. ANNALS OF INTERNAL MEDICINE, 1997, 126 (12) : 946 - 954
  • [5] Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study
    OBrien, TR
    Blattner, WA
    Waters, D
    Eyster, ME
    Hilgartner, MW
    Cohen, AR
    Luban, N
    Hatzakis, A
    Aledort, LM
    Rosenberg, PS
    Miley, WJ
    Kroner, BL
    Goedert, JJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (02): : 105 - 110
  • [6] Changes in plasma HIV RNA levels and CD4(+) lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure
    OBrien, WA
    Hartigan, PM
    Daar, ES
    Simberkoff, MS
    Hamilton, JD
    [J]. ANNALS OF INTERNAL MEDICINE, 1997, 126 (12) : 939 - 945
  • [7] OPRAVIL M, 1997, INT WORKSH HIV DRUG
  • [8] PERDERSEN C, 1997, J ACQ IMMUN DEF SYND, V16, P93
  • [9] HIV-1 RNA levels and the development of clinical disease
    Phillips, AN
    Eron, JJ
    Bartlett, JA
    Rubin, M
    Johnson, J
    Price, S
    Self, P
    Hill, AM
    Akil, B
    Beall, G
    Bellos, N
    Berry, P
    Brummit, C
    Cameron, B
    Cohen, C
    Donabedian, H
    Mayar, K
    McKinley, G
    Sepulveda, G
    Thompson, M
    Tsoukas, C
    Walmsley, S
    Horton, J
    Kerkering, T
    Matthew, E
    Pearce, D
    Peterson, D
    Pottage, J
    Sampson, J
    Smith, W
    Yangco, B
    Cowan, J
    Kaczka, C
    Zameck, R
    Dawson, D
    Pobiner, B
    Gilbert, C
    ScottLennox, J
    DeMasi, R
    Jarrett, P
    Yuen, G
    Esinhart, J
    Quinn, J
    Fallon, MA
    Benoit, S
    [J]. AIDS, 1996, 10 (08) : 859 - 865
  • [10] Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma
    Schuurman, R
    Descamps, D
    Weverling, GJ
    Kaye, S
    Tijnagel, J
    Williams, I
    vanLeeuwen, R
    Tedder, R
    Boucher, CAB
    BrunVezinet, F
    Loveday, C
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (12) : 3016 - 3022